ZA201404836B - Benzyl sulfonamide derivatives useful as mogat-2inhibitors - Google Patents

Benzyl sulfonamide derivatives useful as mogat-2inhibitors

Info

Publication number
ZA201404836B
ZA201404836B ZA2014/04836A ZA201404836A ZA201404836B ZA 201404836 B ZA201404836 B ZA 201404836B ZA 2014/04836 A ZA2014/04836 A ZA 2014/04836A ZA 201404836 A ZA201404836 A ZA 201404836A ZA 201404836 B ZA201404836 B ZA 201404836B
Authority
ZA
South Africa
Prior art keywords
mogat
derivatives useful
sulfonamide derivatives
benzyl sulfonamide
benzyl
Prior art date
Application number
ZA2014/04836A
Other languages
English (en)
Inventor
Maria Rosario Gonzalez-Garcia
Lance Allen Pfeifer
Maria Carmen Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201404836(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA201404836B publication Critical patent/ZA201404836B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2014/04836A 2012-01-31 2014-06-30 Benzyl sulfonamide derivatives useful as mogat-2inhibitors ZA201404836B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Publications (1)

Publication Number Publication Date
ZA201404836B true ZA201404836B (en) 2017-08-30

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/04836A ZA201404836B (en) 2012-01-31 2014-06-30 Benzyl sulfonamide derivatives useful as mogat-2inhibitors

Country Status (27)

Country Link
US (1) US8575352B2 (OSRAM)
EP (1) EP2809651B1 (OSRAM)
JP (1) JP2015511232A (OSRAM)
KR (1) KR20140106750A (OSRAM)
CN (1) CN104066719B (OSRAM)
AP (1) AP2014007794A0 (OSRAM)
AR (1) AR089771A1 (OSRAM)
AU (1) AU2013215468A1 (OSRAM)
BR (1) BR112014018636A8 (OSRAM)
CA (1) CA2859995A1 (OSRAM)
CL (1) CL2014001861A1 (OSRAM)
CO (1) CO7010839A2 (OSRAM)
CR (1) CR20140322A (OSRAM)
DO (1) DOP2014000178A (OSRAM)
EA (1) EA201491276A1 (OSRAM)
ES (1) ES2590929T3 (OSRAM)
GT (1) GT201400167A (OSRAM)
HK (1) HK1199025A1 (OSRAM)
IL (1) IL233712A0 (OSRAM)
MA (1) MA35886B1 (OSRAM)
MX (1) MX2014008599A (OSRAM)
PE (1) PE20141679A1 (OSRAM)
PH (1) PH12014501711A1 (OSRAM)
SG (1) SG11201404106QA (OSRAM)
TW (1) TW201343629A (OSRAM)
WO (1) WO2013116075A1 (OSRAM)
ZA (1) ZA201404836B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
US8993568B2 (en) 2012-01-31 2015-03-31 Eli Lilly And Company Morpholinyl derivatives useful as MOGAT-2 inhibitors
CN104768941B (zh) 2012-11-06 2016-08-24 伊莱利利公司 用作MoGAT-2抑制剂的新苄基磺酰胺化合物
MX389242B (es) 2015-06-15 2025-03-20 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2020145369A1 (ja) 2019-01-11 2020-07-16 塩野義製薬株式会社 Mgat2阻害活性を有するジヒドロピラゾロピラジノン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物
EP1824837B1 (en) * 2004-11-10 2008-08-13 Pfizer, Inc. Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
CA2662766C (en) * 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
EP2078719A4 (en) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
CA2669311C (en) * 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2010216633A1 (en) 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
US8993568B2 (en) 2012-01-31 2015-03-31 Eli Lilly And Company Morpholinyl derivatives useful as MOGAT-2 inhibitors

Also Published As

Publication number Publication date
EP2809651B1 (en) 2016-06-29
CO7010839A2 (es) 2014-07-31
MX2014008599A (es) 2014-08-22
AU2013215468A1 (en) 2014-07-10
TW201343629A (zh) 2013-11-01
CN104066719B (zh) 2016-08-24
EP2809651A1 (en) 2014-12-10
CN104066719A (zh) 2014-09-24
JP2015511232A (ja) 2015-04-16
CA2859995A1 (en) 2013-08-08
KR20140106750A (ko) 2014-09-03
PE20141679A1 (es) 2014-11-08
BR112014018636A8 (pt) 2017-07-11
SG11201404106QA (en) 2014-08-28
CL2014001861A1 (es) 2014-11-07
MA35886B1 (fr) 2014-12-01
EA201491276A1 (ru) 2014-10-30
US8575352B2 (en) 2013-11-05
GT201400167A (es) 2015-05-28
BR112014018636A2 (OSRAM) 2017-06-20
AP2014007794A0 (en) 2014-07-31
US20130197039A1 (en) 2013-08-01
ES2590929T3 (es) 2016-11-24
AR089771A1 (es) 2014-09-17
DOP2014000178A (es) 2014-08-31
PH12014501711A1 (en) 2014-10-13
WO2013116075A1 (en) 2013-08-08
HK1199025A1 (en) 2015-06-19
CR20140322A (es) 2014-08-25
IL233712A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
ZA201409422B (en) Benzimidazole-proline derivatives
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
ZA201408876B (en) Pyrrolotriazinone derivatives
EP2731280B8 (en) Loopback-based built-in-self-test
LT2838883T (lt) Nauji feniltetrahidroizochinolino dariniai
IL233712A0 (en) Sulfonamide derivatives used as mogat–2 inhibitors
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
IL236295A (en) The history of indanesulfamide
EP2817589B8 (fr) Inclinomètre
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
PL2873660T3 (pl) Pochodna indolokarboksyamidu
SG11201404026SA (en) Substituted phenylazole derivative
GB201217285D0 (en) Indole derivatives
ZA201502878B (en) Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
GB201222457D0 (en) Reversed mode
HU4130U (en) Arrangement for facilitate innovation
GB201207119D0 (en) Hamason hinges
GB201215229D0 (en) Tangley